Haemoglobin spray Granulox, which is used in the treatment of chronic wounds, has been added to the NHS Drug Tariff, establishing a new Haemoglobin category. The first of its kind, Granulox is now available on prescription across the UK, infirst Healthcare has announced.
Currently more than 200,000 patients in the UK are living with non-healing wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and post-surgical wounds. Treating patients with chronic wounds costs the NHS between £2.3 and 3.1 billion a year in associated costs including nursing time, dressings, hospital admissions, pain relief and often unnecessary amputations.
Granulox increases levels of oxygen at the wound bed, speeding up the rate of healing in wounds such as venous leg ulcers, by 75% compared to standard care. The treatment also reduces pain by an average of 68% within two weeks.
Independent clinical studies have shown that, when added to standard care, Granulox could save the NHS an average of £2,330 for every diabetic foot ulcer patient and £1,469 for chronic wound patients after six months.
Alistair Copley, Wound Care Manager at infirst Healthcare said: “This is good news for both patients and healthcare professionals. The assessment process undertaken by the NHS Prescription Service is in-depth, challenging and rigorous. Treatments that pass this level of scrutiny have to prove both clinical and cost effectiveness. We are pleased that Granulox has received this recognition and expect to see it being administered across the UK over the coming months.”
The clinical efficacy and cost analysis data have also been reviewed and verified by the Scottish Health Technologies Group, part of NHS Scotland, which recently published its summary of evidence in support of Granulox. It stated that the addition of “Granulox was found to be more effective and less costly than standard care alone.”
Sharon Bateman, Lead Advanced Nurse Practitioner, Northumberland NHS, has been administering Granulox with her patients. She said: “The impact of chronic wounds is not only physical, but social and emotional too. Patients need to know that innovations like this are available to them. Granulox helps wounds to heal, reducing pain, time spent with nurses, and patients can even administer the treatment themselves with support, regaining confidence and independence.”
Granulox Haemoglobin Spray is quick and easy to administer. Granulox should be applied every time the dressing is changed, or at least every three days. The bag-on-valve technology also means that Granulox can be sprayed at any angle, even upside down, for difficult to reach wound areas.